GLTO
Damora Therapeutics Inc
A clinical-stage biotech developing antibody drugs that target a mutated protein called calreticulin, which drives the blood disorders essential thrombocythemia and myelofibrosis. Its lead candidate, DMR-001, was born at Paragon Therapeutics, a firm that launches drug companies from its own research — Damora was the sixth spun out. The company itself was once named Galecto and adopted the Damora name after acquiring the private firm behind DMR-001 in late 2025.
CUSIP: 36322Q107HealthcareUS1 holder
Recent Activity
2021Q3
1 sell
-356.3K shares
Maverick CapitalEXIT
-356.3K shares
2021Q2
1 sell
-126.4K shares(-26.2%)
Maverick CapitalTRIM
-126.4K shares(-26.2%)
2021Q1
1 sell
-7.8K shares(-1.6%)
Maverick CapitalTRIM
-7.8K shares(-1.6%)
Loading more activity...